SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (470)6/25/2007 3:21:40 PM
From: tuck  Read Replies (2) of 523
 
Puzzling, since the PR clearly states that there was one drug-related SAE, but during the CC Dr. Uden just as clearly stated that ther were not any drug-related SAEs. It turns out the patient in question was wakened an hour after taking the drug by a teenage relative, and she drove the teenager to a convenience store at the teenager's request. She later had no recollection of doing this. Very much against protocol, and right when the C Max would be expected to have occurred.

If I was writing the PR, I would have made that much clearer. If this is a sell off related to that, we may have a bargain here. If it's more a matter of how is this better than current therapies, that's different. Whatever, the market seems to have discounted the sleep drug a good deal here. Does that leave us with newsflow from the obesity program as being up next? Perhaps in the form of the DSMB allowing the trial to continue at some point soon? Wilder, you got any color on that?

TIA & Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News